Status:
COMPLETED
Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Schizophrenia
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
* Various studies suggest that patients treated with Olanzapine can experience a substantial weight gain, while no changes have been observed in patients treated with Ziprasidone. Negative consequence...
Eligibility Criteria
Inclusion
- Patients with a primary diagnosis of schizophrenia using the DSM-IV-TR criteria
- Patient's clinical condition should justify treatment initiation with a new antipsychotic drug.
Exclusion
- Patients at immediate risk of committing harm to self or others
- Concurrent treatment with antipsychotic agents after randomization.
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT00239109
Start Date
April 1 2003
End Date
February 1 2007
Last Update
February 21 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bilbao, Vizcaya, Spain
2
Pfizer Investigational Site
Badajoz, Spain
3
Pfizer Investigational Site
Barcelona, Spain
4
Pfizer Investigational Site
Madrid, Spain